Mountain View, CA, October 5, 2004
IMPAC
Medical Systems, Inc. (NASDAQ:IMPCE), a
leading provider of information technology solutions for oncology
care, and Elekta, a world leading supplier of advanced and
innovative radiation oncology and neurosurgery solutions announced
today that they have entered into a Sales Consulting Agreement.
Under the Agreement, Elekta will have rights to offer IMPAC’s
oncology information system products and services, including the
recently released MOSAIQ™ Image-Enabled EMR (electronic medical
record) in select markets around the world.
Elekta will now be able to offer a much broader solution that will
encompass the entire therapy process from initial referral,
through treatment, and into long-term follow-up. By providing
installation, training and support services to information systems
sold by Elekta, IMPAC will expand and accelerate its reach into
the global markets.
Agreement
Strengthens Relationship
IMPAC and Elekta have a rich history of cooperation and
innovation. IMPAC has provided interface solutions to Elekta’s
radiation oncology products and has kept pace with Elekta’s
industry-leading technological achievements for many years. IMPAC
has interfaced to Elekta equipment in ten countries.
In December 2003 IMPAC and Elekta reached agreements to
standardize interfaces for oncology therapeutic equipment based on
the DICOM Standard and earlier this week announced another
collaborative development to improve the performance of IMRT
(Intensity Modulated Radiotherapy).
Open
Systems is Key to Partnership
In this new sales agreement, the companies commit to maintaining
open systems and solutions. While the companies each seek to
benefit from this open systems approach which relies heavily on
their standardization efforts, the key benefactors of this
strategy are the providers of oncology services. “We applaud
Elekta for its open systems commitment. It means practices can
pick best of breed solutions from vendors fully committed to the
emerging standards. For providers it means more choices for future
purchases, easier and faster implementations, and fewer in-house
resources that need to be involved in managing systems,” said
Joseph K. Jachinowski, president and CEO of IMPAC Medical Systems.
“Both Elekta and IMPAC have had long standing commitments to
improve the quality of life for patients. We continue to work with
our partners in the clinic to bring solutions that inspire
clinical confidence in the advancement of radiotherapy techniques
and the fight against serious disease. Elekta has an open-systems
philosophy that offers our customers seamless integration with
freedom to choose the systems that best suit them. This agreement
with IMPAC is an excellent example of this philosophy in action,”
said Laurent Leksell, president and CEO of Elekta.
About IMPAC Medical Systems, Inc.
IMPAC Medical Systems, Inc. is a leading provider of oncology IT
solutions that streamline both clinical and business operations to
help improve the process of delivering quality patient care. With
systems designed for anatomic pathology, medical oncology,
radiation oncology, imaging, clinical laboratory, and cancer
registry, IMPAC supports the entire team of healthcare
professionals who contribute to the care of the cancer patient.
Supporting more than 2500 installations worldwide, IMPAC provides
practical solutions that deliver better overall communication,
process efficiency and quality patient care. For more information
about IMPAC’s products or services, please call 888-GO-IMPAC or
visit www.impac.com.
About Elekta
Elekta is a world-leading supplier of advanced and innovative
radiation oncology and neurosurgery solutions and services for
precise treatment of cancer and brain disorders. Elekta’s
solutions are clinically effective, cost efficient and gentle on
the patient. For additional information about Elekta, please visit
www.elekta.com.
The statements contained in this press
release that are not purely historical are forward looking
statements within the meaning of Section 21E of the Securities and
Exchange Act of 1934, including statements regarding the Company's
expectations, beliefs, hopes, intentions or strategies regarding
the future. Forward looking statements include statements
regarding the Company's review of its revenue recognition policies
and the estimated impact of the proposed financial restatement of
previously report results, possible delisting from The NASDAQ
Stock Market, business strategy, timing of, and plans for, the
introduction of new products and enhancements, future sales,
market growth and direction, competition, market share, revenue
growth, operating margins and profitability. All forward looking
statements included in this document are based upon information
available to the Company as of the date hereof, and the Company
assumes no obligation to update any such forward looking
statement. Actual results could differ materially from the
Company's current expectations. Factors that could cause or
contribute to such differences include the Company's ability to
expand outside the radiation oncology market or expand into
international markets, our inability to recognize revenue from
multiple element software contracts where certain elements have
been delivered, installed and accepted but other elements remain
undelivered, lost sales or lower sales prices due to competitive
pressures, the ability to integrate its products successfully with
related products and systems in the medical services industry,
reliance on distributors and manufacturers of oncology equipment
to market its products, changes in Medicare reimbursement
policies, the integration and performance of acquired businesses,
and other factors and risks discussed in the 10 K/A and other
reports filed by the Company from time to time with the Securities
and Exchange Commission. |
